The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
04/16/2012
. If
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
opportunity click
send
me change notification emails
.
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
printed document.
Document Type:
Grants Notice
Funding Opportunity Number:
W81XWH-13-AFIRM-IIRP
Opportunity Category:
Discretionary
Posted Date:
Apr 16, 2012
Creation Date:
Apr 16, 2012
Original Closing Date for Applications:
Jul 11, 2012
Current Closing Date for Applications:
Jul 11, 2012
Archive Date:
Aug 10, 2012
Funding Instrument Type:
Cooperative Agreement
Grant
Category of Funding Activity:
Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards:
2
Estimated Total Program Funding:
$75,000,000
Award Ceiling:
Award Floor:
CFDA Number(s):
12.420
--
Military Medical Research and Development
Cost Sharing or Matching Requirement:
No
Eligible Applicants
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Additional Information on Eligibility:
Agency Name
Dept. of the Army -- USAMRAA
Description
The Armed Forces Institute of Regenerative Medicine (AFIRM) is dedicated to repairing battlefield injuries through the use of regenerative medicine technologies and associated sciences. Therapies developed by the AFIRM II program are intended to aid traumatically injured Wounded Warriors as well as to benefit those within the civilian sector. One of the goals of the program is to position promising technologies and therapeutic/restorative practices for entrance into human clinical trials. The intent of the AFIRM II program is to fund basic through translational regenerative medicine research and development. Activities acceptable under this award may include basic scientific research, development of animal models, preclinical studies required for initiation of FDA-regulated human clinical trials, and Phase I – II human clinical trials. Therefore, it is not the intent to fund human clinical trials as a major component of this program. It is envisioned that integration of basic science, translational and clinical research efforts will be necessary to advance effective regenerative medicine treatments for combat-related injuries. The Offeror’s organization should actively seek out and establish partnerships with industry to ensure that the technical innovations emerging from the research will transition into clinical applications and result in FDA approved treatments. Offerors are encouraged to seek collaboration with Government laboratories and Medical Centers/Medical Treatment Facilities such as those in the Army, Navy, Air Force, NIH and VA, if mutually beneficial.
Link to Additional Information
If you have difficulty accessing the full announcement
electronically, please contact:
PA HELP: 301-682-5507: help@cdmrp.org
eReceipt HELP: 301-682-5507: help@cdmrp.org
CDMRP Help Desk
Synopsis Modification History
There are currently no modifications for this opportunity.
